Letters in Drug Design & Discovery

Papers
(The H4-Index of Letters in Drug Design & Discovery is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Acknowledgements to Reviewers123
Preparation of Levothyroxine Transdermal Gels and Preliminary Pharmacokinetic Study in Hypothyroidism Rat Model71
Ligand-based Pharmacophore Modeling, Molecular Docking and Simulation Studies for the Exploration of Natural Potent Antiangiogenic Inhibitors Targeting Heat Shock Protein 9032
Piperazine-based Semicarbazone Derivatives as Potent Urease Inhibitors: Design, Synthesis, and Bioactivity Screening31
Repurposing Novel Antagonists for Targeting p7 Viroporin of HCV Using In Silico Approach28
Exploring Novel PLK1 Inhibitors based on Computational Studies of 2,4-Diarylaminopyrimidine Derivatives28
Synthesis and Anticancer Activity of Oral Pt(IV) Prodrugs Containing α-furancarboxylate as an Axial Ligand27
Mechanistic Investigation of Glycyrrhiza uralensis Effects against Respiratory Ailments: Application of Network Pharmacology and Molecular Docking Approaches24
Design, Synthesis and In Vitro Anticancer Activity of Benzo[c]chromen-6- one-linked 1,2,3-Triazole23
Discovery of Structural Prospects of Imidazo[1,5-a]pyrazine Derivatives as BTK Inhibitors Against Cancer: A Computational Study22
Plant Secondary Metabolites as Apoptosis-inducing Agents22
Synthesis, Characterization, and Evaluation of Sulfonium Lipids as Potential Nonviral Gene Vectors21
Computational Insights on Migraine and Anxiety in Association with BDNF20
Screening and Structure-Activity Relationship of Potential Compounds against Proposed Targets of COVID-19 Infection18
Recent Developments, Challenges and Opportunities in Targeting the KRAS Pathway17
Positive Expression of Paired Box 5 (Pax5) was Associated with Age, Tumor Location, and Tumor Size of Patients with Gastrointestinal Neuroendocrine Tumors (NETs)17
0.079307794570923